Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 249 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Itch Clear all
Completed Phase 2 Interventional Results available

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

NCT02651714
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
28
States / cities
Encinitas, California • Encino, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 3, 2026, 1:31 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

NCT06687980
View directory record Official record
Conditions
Lichen Simplex Chronicus
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Anaheim, California • Fremont, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

NCT00750139
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
NAFT-500, Placebo 2-weeks, Naftin 1%, Placebo 4-weeks
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

NCT03580356
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Phase 2 Interventional

Three-Arm Trial of Novel Treatment for Tinea Pedis

NCT03135912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride
Drug
Lead sponsor
South End Skin Care
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 1:31 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females

NCT00856596
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot, Foot Fungus, Ringworm
Interventions
Sertaconazole nitrate cream 2%
Drug
Lead sponsor
Jamaica Hospital Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2009 · Synced Sep 3, 2026, 1:31 AM EDT
Completed No phase listed Observational

Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes

NCT01679015
View directory record Official record
Conditions
Dry Eyes, Allergic Conjunctivitis
Interventions
Not listed
Lead sponsor
Schwartz Laser Eye Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 3, 2026, 1:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Spread of Dermatophytes Among Families

NCT00233493
View directory record Official record
Conditions
Onychomycosis, Tinea Pedis
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Not applicable Interventional Results available

The Role of Skin Care Regimen in Skin Health

NCT03497130
View directory record Official record
Conditions
Itching, Xerosis
Interventions
skin care regimen
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 3, 2026, 1:31 AM EDT
Terminated Phase 4 Interventional Results available

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

NCT05696392
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
30
States / cities
Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 3, 2026, 1:31 AM EDT
Recruiting Phase 2 Interventional

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

NCT06748404
View directory record Official record
Conditions
Immunotherapy-related Pruritus
Interventions
TriCalm Hydrogel®, Triamcinolone acetonide 0.1% cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Not applicable Interventional

Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema

NCT04486742
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Itch CBT
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
8 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 3, 2026, 1:31 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis

NCT01712360
View directory record Official record
Conditions
Tinea Pedis, Tinea Cruris
Interventions
NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult), NAFT600 (adult)
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 3, 2026, 1:31 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

NCT03937869
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Secnidazole
Drug
Lead sponsor
Lupin Research Inc
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
Long Beach, California • Hialeah, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 3, 2026, 1:31 AM EDT
Active, not recruiting Phase 3 Interventional

Linerixibat Long-term Safety, and Tolerability Study

NCT04167358
View directory record Official record
Conditions
Cholestasis
Interventions
Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Davis, California • West Hollywood, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 3, 2026, 1:31 AM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

NCT02654483
View directory record Official record
Conditions
Epidermolysis Bullosa, Pruritus
Interventions
VPD-737, Placebo
Drug · Other
Lead sponsor
Jean Yuh Tang
Other
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 3, 2026, 1:31 AM EDT
Not yet recruiting Phase 2 Interventional

Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

NCT07620561
View directory record Official record
Conditions
Prurigo Nodularis (PN)
Interventions
Lebrikizumab
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 3, 2026, 1:31 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567
View directory record Official record
Conditions
Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 3, 2026, 1:31 AM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

NCT05978063
View directory record Official record
Conditions
Pruritus, Notalgia Paresthetica
Interventions
difelikefalin 2.0 mg tablets, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets, Placebo tablets
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 3, 2026, 1:31 AM EDT